Context Therapeutics (NASDAQ:CNTX) Upgraded at Citizens Jmp
Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...
Stocktwits on MSN2d
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too
Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...
Innovative Growth Potential: Silvan Tuerkcan’s Buy Rating on Context Therapeutics
Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...
Hosted on MSN1d
JMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform Recommendation
Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...
Pharmaceutical Technology10d
CTIM-76 by Context Therapeutics for Ovarian Cancer: Likelihood of Approval
CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
bovnews16d
Context Therapeutics Inc (CNTX) Stock Rated Buy by D. Boral Capital
D. Boral Capital has recently initiated Context Therapeutics Inc (CNTX) stock to Buy rating, as announced on November 25, 2024, according to Finviz. Analyst ratings are significant because they ...
Philly’s year in biopharma: a look back at 2024
Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...
Pharmaceutical Technology10d
CTIM-76 by Context Therapeutics for Endometrial Cancer: Likelihood of Approval
CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Endometrial Cancer.